

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 July 2022 (07.07.2022)



(10) International Publication Number
WO 2022/144836 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61P 35/02 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2021/062494

(22) International Filing Date:

30 December 2021 (30.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20306717.8 31 December 2020 (31.12.2020) EP
63/256,950 18 October 2021 (18.10.2021) US

(71) Applicants: **SANOFI** [FR/FR]; 54 rue La Boétie, 75008 Paris (FR). **INNATE PHARMA** [FR/FR]; 117 avenue de Luminy, F13009 Marseille (FR).

(72) Inventors: **GAUTHIER, Laurent M.**; c/o Innate Pharma, 117 avenue de Luminy, F13009 Marseille (FR). **THIELENS, Ariane**; c/o Innate Pharma, 117 avenue de Luminy, F13009 Marseille (FR). **ROSSI, Benjamin**; c/o Innate Pharma, 117 avenue de Luminy, F13009 Marseille (FR). **AMARA, Céline**; c/o Sanofi, 54 rue La Boétie, 75008 Paris (FR). **NICOLAZZI, Céline**; c/o Sanofi, 54 rue La Boétie, 75008 Paris (FR). **CHIRON, Marielle Blondel**; c/o Sanofi, 54 rue La Boétie, 75008 Paris (FR). **DUFFIEUX, Francis**; c/o Sanofi, 54 rue La Boétie, 75008 Paris (FR). **VIRONE-ODDOS, Angela**; c/o Sanofi, 54 rue La Boétie, 75008 Paris (FR). **BENINGA, Jochen**; c/o Sanofi-Aventis Deutschland GmbH, Patent Department, 65926 Frankfurt am Main (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKP46 AND CD123

(57) Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKP46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).

WO 2022/144836 A1